ERBB2 genetic polymorphism and breast cancer risk in Chinese women: A population-based case-control study

Breast Cancer Research and Treatment

Volumn 110, Issue 1, 2008, Pages 169-176

  Qu, Shimian ^a   Cai, Qiuyin ^a   Gao, Yu Tang ^b   Lu, Wei ^c   Cai, Hui ^a   Su, Yinghao ^a   Wang, Shizhen Emily ^a   Shu, Xiao Ou ^a   Zheng, Wei ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b SHANGHAI CANCER INSTITUTE   (China)

^c Shanghai Center for Disease Control and Prevention   (China)

Author keywords

Breast cancer risk; ERBB2; Genetic polymorphism

Indexed keywords

GENOMIC DNA; ISOLEUCINE; VALINE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER RISK; CHEMICAL ANALYSIS; CHINA; CHINESE; COMPARATIVE STUDY; CONTROLLED STUDY; DNA POLYMORPHISM; EPIDERMAL GROWTH FACTOR RECEPTOR 2 GENE; FEMALE; GENE; GENOTYPE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; POPULATION BASED CASE CONTROL STUDY; PRIORITY JOURNAL; RISK;

ADULT; BREAST NEOPLASMS; CASE-CONTROL STUDIES; FEMALE; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; POLYMORPHISM, GENETIC;

EID: 44849100495     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10549-007-9691-8     Document Type: Article

References (29)

1. Stern DF (2003) ErbBs in mammary development. Exp Cell Res 284:89-98
2. Holbro T et al (2003) The ErbB receptors and their role in cancer progression. Exp Cell Res 284:99-110
3. Yarden Y, Sliwkowski MX (2001) Untangling the ErbB signalling network. Nat Rev Mol Cell Biol 2:127-137
4. Pinkas-Kramarski R et al (1996) Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions. EMBO J 15:2452-2467
5. Slamon DJ et al (1989) Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 244:707-712
6. Lemoine NR et al (1991) Amplification and overexpression of the EGF receptor and c-erbB-2 proto-oncogenes in human stomach cancer. Br J Cancer 64:79-83
7. Revillion F et al (1998) ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 34:791-808
8. Bargmann CI et al (1986) Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 45:649-657
9. Muller WJ et al (1988) Single-step induction of mammary adenocarcinoma in transgenic mice bearing the activated c-neu oncogene. Cell 54:105-115
10. Guy CT et al (1992) Expression of the neu protooncogene in the mammary epithelium of transgenic mice induces metastatic disease. Proc Natl Acad Sci USA 89:10578-10582
11. Saya H et al (1990) Direct sequencing analysis of transmembrane region of human Neu gene by polymerase chain reaction. Mol Carcinog 3:198-201
12. Lemoine NR et al (1990) Absence of activating transmembrane mutations in the c-erbB-2 proto-oncogene in human breast cancer. Oncogene 5:237-239
13. Papewalis J et al (1991) G to A polymorphism at amino acid codon 655 of the human erbB-2/HER2 gene. Nucleic Acids Res 19:5452
14. Xie D et al (2000) Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 92:412-417
15. Baxter SW Campbell IG (2001) Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93:557-559
16. Hishida A et al (2002) Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 94:1807-1808
17. Keshava C et al (2001) Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett 173:37-41
18. Kean-Cowdin R et al (2001) Germ-line HER-2 variant and breast cancer risk by stage of disease. Cancer Res 61:8393-8394
19. Millikan R et al (2003) HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat 79:355-364
20. Montgomery KG et al (2003) The HER2 I655V polymorphism and risk of breast cancer in women < age 40 years. Cancer Epidemiol Biomarkers Prev 12:1109-1111
21. Wang-Gohrke S, Chang-Claude J (2001) Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 93:1657-1659
22. Nelson SE et al (2005) A case-control study of the HER2 Ile655Val polymorphism in relation to risk of invasive breast cancer. Breast Cancer Res 7:R357-R364
23. Zubor P et al (2006) HER-2 [Ile655Val] polymorphism in association with breast cancer risk: a population-based case-control study in Slovakia. Neoplasma 53:49-55
24. Kamali-Sarvestani E et al (2004) Ile to Val polymorphism at codon 655 of HER-2 gene and breast cancer risk in Iranian women. Cancer Lett 215:83-87
25. Gao YT et al (2000) Association of menstrual and reproductive factors with breast cancer risk: results from the Shanghai Breast Cancer Study. Int J Cancer 87:295-300
26. Wang SE et al (2006) HER2 kinase domain mutation results in constitutive phosphorylation and activation of HER2 and EGFR and resistance to EGFR tyrosine kinase inhibitors. Cancer Cell 10:25-38
27. Colditz GA, Baer H, Tamimi RM (2006) Breast cancer. In: Schottenfeld D, Fraumeni JF Jr (eds) Cancer epidemiology and prevention, 3rd edn. Oxford University Press, pp 995-1012
28. Siegel PM et al (1994) Novel activating mutations in the neu proto-oncogene involved in induction of mammary tumors. Mol Cell Biol 14:7068-7077
29. Bargmann CI et al (1988) Oncogenic activation of the neuencoded receptor protein by point mutation and deletion. Embo J 7:2043-2052